Should you sell Bristol-Myers Squibb (NYSE: BMY) today?

The decision to sell a stock you've researched and followed for months or years is never easy. But if you fall in love with your stock holdings, you risk becoming vulnerable to confirmation bias -- listening only to information that supports your theories, and rejecting any contradictions.

In 2004, longtime Fool Bill Mann called confirmation bias one of the most dangerous components of investing. This warning has helped my own personal investing throughout the Great Recession and the recent volatility throughout early August. In this series, I want to help you identify potential sell signs on popular stocks within our 4-million-strong Fool.com community.

Today I'm laser-focused on Bristol-Myers Squibb, ready to evaluate its price, valuation, margins, and liquidity. Let's get started!

Don't sell on price
Over the past 12 months, Bristol-Myers Squibb has risen 6.3% versus an S&P 500 return of 9.1%. Investors in Bristol-Myers Squibb are no doubt disappointed with their returns, but is now the time to cut and run? Not necessarily. Short-term underperformance alone is not a sell sign. The market may be missing the critical element of your Bristol-Myers Squibb investing thesis. For historical context, let’s compare Bristol-Myers Squibb's recent price to its 52-week and five-year highs. I've also included a few other businesses in the same or related industries:

Company

Recent Price

52-Week High

5-Year High

Bristol-Myers Squibb $27.97 $29.73 $32.40
Pfizer (NYSE: PFE) $17.86 $21.45 $28.60
Merck (NYSE: MRK) $31.34 $37.68 $61.60
Abbott Laboratories (NYSE: ABT) $49.63 $54.24 $61.10

Source: Capital IQ, a division of Standard & Poor's.

As you can see, Bristol-Myers Squibb is down a little from its 52-week high. If you bought near the peak, take a moment to think back to why you bought it in the first place. If your reasons still hold true, you shouldn't sell based on this information alone.

Potential sell signs
First up, we'll get a rough idea of Bristol-Myers Squibb's valuation. I'm comparing Bristol-Myers Squibb's recent P/E ratio of 14.5 to where it's been over the past five years.

Bmyperatios

Source: Capital IQ, a division of Standard & Poor's.

Bristol-Myers Squibb's P/E is lower than its five-year average, which could indicate the stock is undervalued. A low P/E isn't always a good sign, since the market may be lowering its valuation of the company because of less attractive growth prospects. It does indicate that, on a purely historical basis, Bristol-Myers Squibb looks cheap.

Now, let's look at the gross margins trend, which represents the amount of profit a company makes for each $1 in sales, after deducting all costs directly related to that sale. A deteriorating gross margin over time can indicate that competition has forced the company to lower prices, that it can't control costs, or that its whole industry's facing tough times. Here is Bristol-Myers Squibb's gross margin over the past five years:

Bmygrossmargins

Source: Capital IQ, a division of Standard & Poor's.

Bristol-Myers Squibb is having no trouble maintaining and even growing its gross margin, which tends to dictate a company's overall profitability. This is solid news; however, Bristol-Myers Squibb investors need to keep an eye on this over the coming quarters. If margins begin to dip, you'll want to know why.

Next, let's explore what other investors think about Bristol-Myers Squibb. We love the contrarian view here at Fool.com, but we don't mind cheating off our neighbors every once in a while. For this, we'll examine two metrics: Motley Fool CAPS ratings and short interest. The former tells us how Fool.com's 180,000-strong community of individual analysts rate the stock. The latter shows what proportion of investors are betting that the stock will fall. I'm including other peer companies once again for context.

Company

CAPS Rating (out of 5)

Short Interest (% of Float)

Bristol-Myers Squibb ***** 2.1
Pfizer **** 0.8
Merck **** 0.7
Abbott Laboratories ***** 0.9

Source: Capital IQ, a division of Standard & Poor's.

The Fool community is rather bullish on Bristol-Myers Squibb. We typically like to see our stocks rated at four or five stars. Anything below that is a less-than-bullish indicator. I highly recommend you visit Bristol-Myers Squibb's stock pitch page to see the verbatim reasons behind the ratings.

Here, short interest is at a mere 2.1%. This typically indicates few large institutional investors are betting against the stock.

Now, let's study Bristol-Myers Squibb's debt situation, with a little help from the debt-to-equity ratio. This metric tells us how much debt the company's taken on, relative to its overall capital structure.

Bmytotaldebttoequity

Source: Capital IQ, a division of Standard & Poor's.

Bristol-Myers Squibb has done a good job of reducing its debt over the past five years. When we take into account increasing total equity over the same time period, this has caused debt-to-equity to decrease, as seen in the above chart. Based on the trend alone, that's a good sign. I consider a debt-to-equity ratio below 50% to be healthy, though it varies by industry.  Bristol-Myers Squibb is currently below this level, at 34.2%.

The last metric I like to look at is the current ratio, which lets investors judge a company's short-term liquidity. If Bristol-Myers Squibb had to convert its current assets to cash in one year, how many times over could the company cover its current liabilities? As of the last filing, Bristol-Myers Squibb has a current ratio of 1.99. This is a healthy sign. I like to see companies with current ratios equal to or greater than 1.5.

Finally, it’s highly beneficial to determine whether Bristol-Myers Squibb belongs in your portfolio -- and to know how many similar businesses already occupy your stable of investments. If you haven't already, be sure to put your tickers into Fool.com's free portfolio tracker, My Watchlist. You can get started right away by clicking here to add Bristol-Myers Squibb.

The final recap

Bmysellingrecap

Bristol-Myers Squibb has failed none of the quick tests that would make it a sell. This is great, but does it mean you should hold your Bristol-Myers Squibb shares? Not necessarily. Just keep your eye on these trends over the coming quarters.

In order to do that, I strongly recommend clicking here to add Bristol-Myers Squibb to My Watchlist  to help you keep track of all of our ongoing coverage of the company.